Key Takeaways
- U.S. exit run rate of $1 billion reaffirmed: Management held the FY27 exit target, citing multiple pathways through Ventolin and Advair ramp-ups plus three pending approvals, though it declined to split the contribution between approved and unapproved assets.
- India branded prescription beat the market: 14.6% H1 growth vs IPM 14.3%, driven by chronic therapies; GLP-1 adoption is accelerating with Yurpeak now the second-largest brand in the GLP rankings and month-on-month growth of 5–10% expected to continue.
- Respiratory pipeline is converting from promise to product: Generic Advair approved in Q2 and launching Q3; Ventolin launched but supply is ramping from a new facility, so the revenue curve is back-half loaded. Two more respiratory assets and one peptide are pending approval this financial year.
- Margins are climbing back as guided: EBITDA margin improved 200 bps sequentially to 18.7%, and management expects sequential expansion to continue through Q4, delivering the 18.5%–20% full-year band for FY27.
- What to watch next quarter: Whether Ventolin supply scales exponentially as promised, the timing of the three pending U.S. approvals, and whether the South Africa tender business recovers after the favorable court ruling.
The $1 Billion U.S. Exit Rate: Pathways and Dependencies
- The target is intact but the mix is undisclosed: Management reiterated the $1 billion annualized exit run rate but declined to split the ramp-up between already-approved products (Ventolin, Advair) and the three pending approvals, calling product-wise guidance "a little bit hard." The exact combination depends on approval timing.
- Ventolin: the volume story is back-half loaded. Launched in Q1 from a new U.S. manufacturing facility, Ventolin holds 22% commercial share on Proventil generics, but supply must scale exponentially from current levels to capture a much higher share of the ~2.4 crore unit market where Cipla is the only generic.
- Advair: approved, launching Q3. The first DPI approval from Cipla's U.S.-based manufacturing network, it will build revenue through Q3 and Q4.
- Three pending approvals carry the upside risk: Two more respiratory assets and one key peptide opportunity are expected this financial year. One respiratory asset is from the Goa facility (no ramp-up needed); the other is from the U.S. facility but management expects no ramp-up challenges given the team's Ventolin/Advair experience. Exact approval dates are not in management's control.
- Lanreotide is out of the FY27 picture: Two parallel paths are being pursued (Pharmathen remediation plus a new North America site), but neither is included in the exit run rate.
- Pembrolizumab biosimilar is the long-range anchor: Licensed from Qilu Pharma for North America, Cipla expects to file next year and be among the first wave of launches around the ~2029 patent expiry, with a "very significant contribution" to North America once it reaches market.
Achin Gupta: "We have different pathways to get there. And therefore, we are maintaining the same guidance at this point in time."
India Business: Chronic Strength, GLP-1 Momentum
- Branded prescriptions grew 15% on strong volume growth, brand equity, and new product introductions. Chronic therapies led: antidiabetes grew 50% (including GLP-1), dermatology 16%, respiratory and urology 11% each.
- GLP-1 adoption is accelerating and management sees no saturation: Tirzepatide (Yurpeak) became the second-largest brand in GLP rankings, with month-on-month growth of 5–10% expected to continue steadily.
- Trade generics delivered strong double-digit sequential growth on 15-plus new launches, though year-on-year growth was only mid-single digits due to seasonality and cost factors. Steady growth is expected to continue.
- Consumer health brands consolidated leadership: Nicotex, Omnigel, and Cipladine posted healthy secondary growth and improved operating profitability. High single-digit growth in H1 reflected cost and pricing headwinds that are being mitigated; double-digit growth is expected going forward.
- Oncology trade margin cap: Discussion is ongoing; management does not believe it will have a significant impact and will wait for a directive before commenting further.
Achin Gupta: "We are seeing month-on-month growth rates of somewhere between 5% to 10%. So we expect that trajectory to continue. Yurpeak has become the second largest brand in the rankings on GLP. And I think we don't expect any saturation on this front."
Respiratory Franchise: Barriers, Approvals, and the Symbicort Question
- The thesis rests on complexity as a moat: Management emphasized that respiratory is a complex, FDA-classified opportunity with high entry barriers that typically keeps it a fewer-player market, not a highly competitive commodity generic space.
- Ventolin and Advair are the near-term proof points: Both are approved from the new U.S. manufacturing network, validating Cipla's differentiated respiratory capabilities. Ventolin's ramp is supply-constrained, not demand-constrained.
- Symbicort is a large opportunity but timing is uncertain: Management sees significant potential and confidence in contribution, but noted that competitive dynamics could change by the time of entry. Cipla declined to say whether it has ever received a CRL on Symbicort, calling it "competition sensitive."
- Ellipta franchise assets are later-stage: They are not among the current pending approvals.
Achin Gupta: "Respiratory is a complex opportunity, which as per the FDA classification also it is, right? So there are entry barriers and therefore, it typically remains a fewer player market... it is typically not a very high competitive commodity generic market."
Margins: Sequential Expansion on Track
- EBITDA margin improved 200 bps sequentially to 18.7%, in line with guidance. Gross margin rose 7% QoQ to 64.4%, supported by improved product mix.
- Total expenses rose 4% QoQ, reflecting planned investment in upcoming product launches and manufacturing readiness. The Q2 expense base is always higher than Q1, and no one-offs were called out.
- The full-year band of 18.5%–20% is reaffirmed, with sequential expansion expected in both remaining quarters. Unusually, Q4 margins are expected to improve over Q3, driven by the U.S. ramp-up.
- R&D spend stays within 6%–7% of revenue for FY27; absolute investment grows as revenue grows. Next year's guidance will come with next year's numbers.
Pipeline Beyond Respiratory: Biosimilars, Peptides, and Complex Generics
- Four biosimilar programs are under development for global markets. The first asset has FDA consultation that Phase III will not be needed; management expects similar waivers for the remaining programs. Cipla plans to add 1–2 biosimilar assets internally each year and selectively in-license nearer-term opportunities like Pembrolizumab.
- The U.S. pipeline is 45–50 complex filings over three years, with no plain-vanilla generics. The peptide opportunity pending approval this year is one example of the complexity tilt.
- CTTQ partnership adds a bispecific ADC (HER2-targeted) for India and emerging markets, strengthening the innovative oncology portfolio.
- Aspergen, the majority Cipla-owned joint venture with Kemwell, is the in-house biosimilar manufacturing entity and is scaling up.
- Pithampur status: The follow-up GMP inspection produced 7 observations but no repeats and no data integrity issues. If the site converts to Voluntary Action Indicated, it will open up further opportunities. New approvals have been mitigated via U.S. sites or Goa.
Regional Markets: South Africa Reset, EMEU Resilience
- South Africa private market grew 6.5% secondary, outperforming the 5% market, driven by key therapies and new launches. Reported numbers dipped partly due to an accounting change (restates top line, preserves EBITDA) and partly due to a tender loss. A favorable court ruling received a few days before the call is expected to correct the tender business.
- EMEU delivered $101 million in revenue with resilience through strong execution and cost discipline despite challenging geopolitics and market-specific headwinds. The focus is driving top-line growth while maintaining margin trajectory.
- Cash deployment is selective and geographically tilted: Cipla is looking to acquire complex or differentiated assets, more likely in North America or Europe. India is harder due to Cipla's #1 volume position and scarcity of non-overlapping assets.
Achin Gupta: "We evaluate a lot. We're just being selective so that we make the right moves, which will help the business grow from a longer-term window as well."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.S. exit run rate | $1 billion annualized revenue run rate | FY27 exit |
| U.S. launches | 3 additional significant launches: 2 respiratory assets, 1 peptide | FY27 |
| Generic Advair launch | Launch and begin revenue build | Q3 FY27 |
| Ventolin supply ramp | Exponential increase from current levels to capture much higher share of ~2.4 crore unit market | Through FY27 |
| EBITDA margin | 18.5%–20% full-year band; sequential expansion in remaining quarters, with Q4 improving over Q3 | FY27 |
| R&D spend | 6%–7% of revenue | FY27 |
| U.S. pipeline filings | 45–50 complex filings for North America | Next 3 years |
| Pembrolizumab biosimilar filing | File for approval, targeting first-wave launch | File next year; launch ~2029 |
| Biosimilar pipeline additions | Add 1–2 assets internally each year plus selective in-licensing | Ongoing |
| Lanreotide | Not contributing this financial year; two parallel paths pursued | Beyond FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹7,404 cr, +4% QoQ |
| One India revenue growth | 12% YoY |
| Branded prescription growth | 15% (IQVIA YTD Sep '26) |
| EBITDA margin (excl. other income) | 18.7%, +200 bps QoQ |
| Gross margin after material costs | 64.4%, +7% QoQ |
| Total expenses | ₹3,382 cr, +4% QoQ |
| R&D spend | ₹423 cr, 5.7% of revenue |
| Profit after tax | ₹878 cr, 11.9% of sales, +77 bps QoQ |
| Effective tax rate | 27.2% |
| North America quarterly revenue | $172 mn, +$10 mn QoQ |
| EMEU quarterly revenue | $101 mn |
| U.S. Albuterol MDI market share | 22% (IQVIA, last week of Sep '26) |
| South Africa private market secondary growth | 6.5% vs market 5% (IQVIA MAT Aug '26) |
| Chronic portfolio mix | 60.3% (IQVIA MAT Sep '26) |
| Net cash balance | ₹9,823 cr as of 30 Sep '26 |
| Debt (incl. lease liabilities) | ₹699 cr as of 30 Sep '26 |
| Full-year EBITDA margin guidance | 18.5% to 20%, maintained |
| Full-year R&D spend guidance | 6% to 7% of revenue |
| Full-year ETR guidance | 27% to 27.5% |
| U.S. exit run rate guidance | $1 bn annualized, maintained |
| U.S. filings target | 45 to 50 over next 3 years, vs ~10 average previously |
| Biosimilar assets under development | 4 |
| Trade generics YoY growth | Mid-single digits |
| India branded prescription H1 FY27 growth | 14.6% vs market 14.3% |
| GLP-1 portfolio share of domestic sales | ~10% (per an analyst's statement) |